MALVERN, Pa. - Neuronetics , Inc. (NASDAQ: NASDAQ:STIM), a medical technology firm specializing in neurohealth solutions, has entered into an exclusive agreement with Transformations Care Network (TCN), a prominent mental health care provider. The partnership will see Neuronetics become the sole provider of transcranial magnetic stimulation (TMS) equipment to TCN, expanding the availability of their NeuroStar TMS therapy.
The collaboration, announced today, is set to enhance the treatment options for patients with major depressive disorder (MDD), including those with treatment-resistant depression (TRD). NeuroStar TMS therapy is a non-invasive, FDA-cleared treatment option for adults with MDD and is considered a significant addition to TCN's mental health services.
Keith J. Sullivan, President and CEO of Neuronetics, expressed enthusiasm about the extended commercial relationship, emphasizing the growing demand for mental health services and the role of NeuroStar TMS in TCN's expansion plans. Brian Wheelan, CEO of TCN, highlighted the partnership as a key step in integrating advanced treatments into their services, aiming to provide exceptional care and access to the best mental health solutions.
TCN operates an extensive network of facilities across six states and has a strategic plan for further growth. The five-year exclusive agreement with Neuronetics is pivotal in making advanced NeuroStar TMS treatments more accessible to patients struggling with MDD.
NeuroStar TMS therapy has shown efficacy in cases where traditional pharmacological treatments have been insufficient. The integration of this therapy into TCN's service offerings is indicative of a commitment to advanced technologies and treatments that can improve patient outcomes in mental health care.
This partnership is based on a press release statement.
InvestingPro Insights
As Neuronetics, Inc. (NASDAQ: STIM) cements its partnership with Transformations Care Network, the company's financial health and stock performance become essential indicators for potential investors and stakeholders monitoring the impact of such strategic alliances. Neuronetics currently boasts a market capitalization of $117.24 million, reflecting its standing in the medical technology sector. Despite not offering dividends and lacking profitability in the last twelve months, Neuronetics has experienced significant price returns, with a 34.0% increase over the last week and a remarkable 162.75% uptick over the past six months, trading near its 52-week high at 94.59% of the peak value.
According to the latest InvestingPro Tips, Neuronetics operates with a moderate level of debt, ensuring its financial stability, and its liquid assets exceed short-term obligations, suggesting a solid financial footing for immediate operational needs. These insights are vital for understanding the company's capacity to sustain and grow its partnership with TCN. However, two analysts have revised their earnings downwards for the upcoming period, and the company is not expected to be profitable this year, which could be cause for investor caution.
For those considering a deeper dive into Neuronetics' financials and future prospects, InvestingPro offers additional insights, with 7 more InvestingPro Tips available at: https://www.investing.com/pro/STIM. Use the exclusive coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking a comprehensive analysis that could guide investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.